COVID-19 Vaccines Global Access(COVAX) is a global collaboration to ensure equitable global access to COVID-19 vaccines. It is co-led by GAVI, the Global Alliance for Vaccines and Immunization, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, and others. Its global initiative is working with governments and manufacturers to ensure that COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.
COVAX is undertaking the largest, most complex roll out of vaccines in history, delivering them faster, to more countries and in greater volumes than has ever been managed before. As of today, there have been over 77 million doses shipped through COVAX to 127 economies globally, including 75 countries eligible for support through the Gavi COVAX Advance Market Commitment (COVAX AMC). This is a significant achievement, but there are enormous inequities, and we have much work ahead of us if we are to fulfil our goal of ending the acute phase of the pandemic everywhere. We also urgently need all countries that have surplus doses to share them so we can ensure those that are most at risk everywhere can be protected.
Nobody is safe until everyone is safe because infectious diseases do not respect borders. The International Chamber of Commerce published a study in January 2021 showed that if advanced economies continue to prioritise vaccination of their susceptible populations without ensuring equitable vaccination for developing economies, the total cost to the world varies between US$ 1.5–9.2 trillion. Therefore, global equitable access to vaccines is the only way to lessen the public health and economic impact of the pandemic on individuals, communities, and nations.
COVAX is already showing that it is the right mechanism to make equitable access to vaccines possible, but obviously we need much more to meet the urgency of the pandemic. This is why we are calling on countries with much vaccine supplies to share doses and trade early places in production queues with COVAX, on governments to abandon all export restrictions on raw materials at a time when we need international cooperation to end the pandemic and a fully financed AMC requiring at least an additional US$1.6 billion by June in order to lock in supplies for 2021 and early 2022.
Gavi welcomes news that Sinopharm has recently been granted WHO Emergency Use Listing, as this means the world has yet another safe and effective tool in the fight against this pandemic. Gavi is open to procuring any vaccine so long as it has achieved necessary approvals and we very much hope that Sinopharm can play a front-line role in COVAX’s global push to end the acute phase of the pandemic.
During the 73rd Session of the World Health Organization’s (WHO) World Health Assembly (WHA) last May, Chinese President Xi Jinping announced, “COVID-19 vaccine development and deployment in China, when available, will be made a global public good.” China has joined COVAX and committed to provide 10 million doses of vaccines to developing nations. It is an important step towards the objective and we welcome China’s commitment.
Given China’s active leadership throughout the pandemic, alongside extensive ongoing vaccine research efforts, we believe there is much room for both Chinese public and private actors to support equitable access to vaccines by participating in both the COVAX Facility and the Gavi COVAX AMC. Their support would go a long way towards ensuring equitable access to COVID-19 vaccines. To prepare for the rising threat of new variants, we also encourage potential vaccine developers to submit promising candidates for consideration for COVAX research and development.
The global access to vaccines is not happening fast enough, and it’s in everyone’s interest that we get there sooner. Moreover, any delay will also prolong the economic misery, by ensuring that efforts to resume commerce, trade and travel continue to stall. We urgently need countries with the largest vaccine supplies to share doses and trade early places in production queues with COVAX, so we can meet COVAX’s immediate supply needs. Manufacturers and governments should facilitate the fulfilment of deals so COVAX can deliver on its goal of at least 2 billion doses in 2021.
(The author is the CEO of Gavi, the Vaccine Alliance)
more recommended stories
Widening wealth gap mirrors poor human rights situation in U.S.
The consumer price index of the.
Gunshots shatter illusion of American-style human rights
Gun violence brought another tragedy to.
Undeserved national tragedy—Over 1 mln COVID-19 deaths in the U.S.
The U.S. boasts the world’s richest.
China’s whole-process people’s democracy revolutionizes understandings on democracy
The People’s Republic of China (PRC).
Racism against Asian Americans an ugly thread in U.S. history
“In the U.S., there was a.
U.S., more than any other country, should reflect on hypocritical democracy, deteriorating human rights situation
The U.S. has thoroughly exposed its.
Japan severely breaches obligations under international law by persisting in discharge of nuclear-contaminated water into ocean
Japan is being extremely selfish and.
U.S. is trampling on international order by stoking bloc confrontation
Facts have proven time and again.
Pursuing absolute security would only make worse security dilemma
NATO’s response to the Ukraine crisis.
U.S. Cold War mentality undermines international security cooperation
U.S. President Joe Biden recently delivered.